Who is sponsoring NCT05568160?

NCT05568160 is sponsored by Centre Hospitalier Universitaire Dijon.

What drugs are being tested in NCT05568160?

Interventions in NCT05568160: Vasopressin, Norepinephrine, Collection of clinical data, Quality of Life Questionnaire EQ-5D.

Is NCT05568160 still recruiting?

NCT05568160 is currently active, enrolled. Last updated 16 December 2025.

Last reviewed 2025-12-16 · How we verify

NCT05568160: NOVACC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Randomized Double-blind Study Evaluating the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation

Active, enrolled Phase 3 Last updated 16 December 2025

What this trial tests

Phase 3 trial testing Vasopressin in Scheduled Cardiac Surgery With Extracorporeal Circulation in 840 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 January 2023

Primary endpoint
1 March 2026

1 March 2026

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Dijon
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	840
Start date	2 January 2023
Primary completion	1 March 2026
Estimated completion	1 March 2026
Sites	1 location across France

Drugs / interventions tested

Vasopressin — full drug profile →
Norepinephrine (NOREPINEPHRINE) — full drug profile →
Collection of clinical data
Quality of Life Questionnaire EQ-5D

Conditions studied

Scheduled Cardiac Surgery With Extracorporeal Circulation — all drugs for Scheduled Cardiac Surgery With Extracorporeal Circulation →
Vasoplegic Syndrome — all drugs for Vasoplegic Syndrome →

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

70 and older, any sex, with Scheduled Cardiac Surgery With Extracorporeal Circulation or Vasoplegic Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Occurrence of a renal complication or death
Time frame: From the onset of the vasoplegic syndrome until 7 days after

Sponsor's own description

This is a randomized, double blind, multicenter study following surgery with extracorporeal circulation to compare blood pressure optimization with vasopressin versus noradrenaline. It is planned to include 840 patients in order to have 420 patients with vasoplegic syndrome. The primary objective of this study is to determine whether the use of vasopressin to maintain blood pressure following cardiac surgery decreases the number of patients with acute renal failure and/or death compared with the usual use of norepinephrine. Participation in the study involves daily follow-up at D1, D2, and D7 of the onset of the syndrome and then follow-up at D30 and D90.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial).
Guinot PG, Desebbe O, Besch G, Guerci P, et al · · 2024 · cited 5× · PMID 38492626 · DOI 10.1016/j.ahj.2024.03.008
The therapeutic horizon of acute kidney injury in critical care: exploring pathology, promises, pitfalls, and progress.
Vogelaar Y, Mourisse L, Pickkers P. · · 2025 · PMID 41191836 · DOI 10.1097/mcc.0000000000001331

Verify or expand the search:

Other trials of Vasopressin

Trials testing the same drug.

NCT06426407 — Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator · terminated
NCT06547892 — Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU · Phase 2 · recruiting
NCT06419075 — Tranexamic Acid in Vaginal Reconstructive Surgery · Phase 4 · withdrawn
NCT06290596 — Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy · Phase 4 · unknown
NCT06329037 — The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study · NA · recruiting

Other Centre Hospitalier Universitaire Dijon trials

Trials by the same sponsor.

NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05568160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
Last refreshed: 16 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05568160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing